Table 1.
Summary of the patient characteristics across all countries.
| 2003–05 | 2006–09 | 2010–13 | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
|
| |||
| Total | 2874 | 6248 | 7840 |
| Age | |||
| ≤30 | 736 (25) | 1505 (24) | 2087 (26) |
| 31–40 | 1440 (50) | 2865 (46) | 3343 (43) |
| 41–50 | 508 (18) | 1272 (20) | 1555 (20) |
| 51+ | 190 (7) | 606 (10) | 855 (11) |
| Median [IQR] | 35 [30, 40] | 36 [31, 42] | 36 [30, 43] |
| Sex | |||
| Male | 2149 (75) | 4312 (69) | 5176 (66) |
| Female | 721 (25) | 1931 (31) | 2657 (34) |
| Transgender | 4 (<0.2) | 5 (<0.1) | 7 (<0.1) |
| Mode of HIV exposure | |||
| Heterosexual | 2529 (88) | 5272 (85) | 5748 (73) |
| Homosexual | 111 (4) | 405 (6) | 784 (10) |
| Injecting drug user | 84 (3) | 125 (2) | 571 (7) |
| Other/Unknown | 150 (5) | 446 (7) | 737 (10) |
| HCV (ever) | |||
| Negative | 754 (26) | 2609 (42) | 4093 (52) |
| Positive | 80 (3) | 171 (3) | 776 (10) |
| Not tested | 2040 (71) | 3468 (55) | 2971 (38) |
| HBV (ever) | |||
| Negative | 939 (33) | 2869 (46) | 4702 (60) |
| Positive | 108 (4) | 305 (5) | 473 (6) |
| Not tested | 1827 (63) | 3074 (49) | 2665 (34) |
| Pre-ART CD4 (cells/μL) | |||
| ≤50 | 708 (25) | 1295 (21) | 1620 (21) |
| 51–100 | 543 (19) | 915 (15) | 833 (10) |
| 101–200 | 793 (27) | 1748 (28) | 1307 (17) |
| >200 | 377 (13) | 1325 (21) | 2990 (38) |
| Not tested | 453 (16) | 967 (15) | 1094 (14) |
| Median [IQR] | 96 [45, 171] | 128 [52, 201] | 172 [53, 286] |
| Pre-ART viral load (copies/mL) | |||
| ≤105 | 191 (7) | 458 (7) | 1073 (14) |
| >105 | 204 (7) | 518 (8) | 1154 (15) |
| Not tested | 2479 (86) | 5272 (85) | 5613 (71) |
| Median [IQR] | 106 000 [32 000, 261 000] | 114 000 [29 785, 351 500] | 110 564 [30 563, 402 000] |
| First ART regimen | |||
| NRTI+NNRTI | 2719 (95) | 5930 (95) | 7381 (95) |
| NRTI+PI | 148 (5) | 290 (5) | 381 (5) |
| Other | 7 (<0.3) | 28 (<0.5) | 78 (1) |
| Previous mono/dual therapy | |||
| No | 2632 (92) | 6053 (97) | 7680 (98) |
| Yes | 242 (8) | 195 (3) | 160 (2) |